And more biotech news from The Readout newsletter
Espace publicitaire · 300×250
STAT+: France rebuffs Trump over drug-pricing boast
STAT | Reporting from the frontiers of health and medicine • Publié le 22 janvier 2026
Espace publicitaire · 728×90
Articles similaires
🇬🇧 → 🇫🇷
A measles outbreak and hospitals’ financial troubles
This week on "The Readout LOUD" podcast: Why is the U.S. at risk of losing its measles elimination status? And what did top CMS official Mehmet Oz tell hospital executives…
🇬🇧 → 🇫🇷
Opinion: I ask my patients what they’re grateful for. Recently, three of them cried
Joseph Tucker, an infectious disease doctor, asks every patient what they’re grateful for. Sometimes, their responses surprise him.
🇬🇧 → 🇫🇷
Opinion: A Goldilocks approach to centralization of high-risk pathogen research
A resilient biosafety system depends on distributed expertise, not centralized control.
🇬🇧 → 🇫🇷
What RFK Jr.’s milk mustache says about the historic power of dairy in the U.S.
Milk is getting an AI-assisted push from federal officials. Will other foods favored by MAHA get similar treatment?
🇬🇧 → 🇫🇷
STAT+: Anthony Letai says NCI is more stable than perceived and is heading for a big year
Anthony Letai says the National Cancer Institute is more stable than perceived and is heading for a big year.
🇬🇧 → 🇫🇷
U.S. makes exit from the WHO complete
The U.S. withdrawal from the WHO became official Thursday, formalizing a fissure between the Trump administration and the Geneva-based global health agency.
🇬🇧 → 🇫🇷
STAT+: As FDA raises bar in rare diseases, pivotal moment nears for RegenxBio
A prominent biotech investor weighs in on the pros and the cons of the FDA's new regime.
🇬🇧 → 🇫🇷
The rise of unproven, potentially dangerous autism treatments
And other health news from Morning Rounds today